CKD Bio Corp. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was KRW 0.0006 million compared to negative sales of KRW 0.00011 million a year ago. Net loss was KRW 3,500.23 million compared to KRW 4,259.98 million a year ago. Basic loss per share from continuing operations was KRW 638 compared to KRW 777 a year ago. Basic loss per share was KRW 638 compared to KRW 777 a year ago.
For the nine months, negative sales was KRW 0.00071 million compared to KRW 0.00012 million a year ago. Net loss was KRW 9,628.27 million compared to KRW 5,742.85 million a year ago. Basic loss per share from continuing operations was KRW 1,755 compared to KRW 1,047 a year ago. Basic loss per share was KRW 1,755 compared to KRW 1,047 a year ago.